Compare GFAI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | QNCX |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.5M |
| IPO Year | 2020 | 2019 |
| Metric | GFAI | QNCX |
|---|---|---|
| Price | $0.35 | $31.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 152.7K | 33.9K |
| Earning Date | 04-21-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | ★ N/A | $11.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.08 |
| 52 Week High | $1.38 | $33.11 |
| Indicator | GFAI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 91.24 |
| Support Level | $0.31 | $0.89 |
| Resistance Level | $0.42 | N/A |
| Average True Range (ATR) | 0.03 | 2.25 |
| MACD | 0.01 | 0.56 |
| Stochastic Oscillator | 62.33 | 94.72 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.